Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
FibroBiologics, Inc. operates as a clinical-stage cell therapy company that focuses on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs. The company develops CybroCell for degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for treating wound healing. Its early-stage research programs include CYTER915 which is designed to regenerate or reinvigorate production of the thymus and/or spleen; and TCB190 for the treatment of cancers. The company was incorporated in 2021 and is based in Houston, Texas. FibroBiologics, Inc. operates as a subsidiary of Spinalcyte Llc.
| Last: | $0.3294 |
|---|---|
| Change Percent: | 16.97% |
| Open: | $0.3 |
| Close: | $0.2816 |
| High: | $0.3346 |
| Low: | $0.3 |
| Volume: | 856,745 |
| Last Trade Date Time: | 02/27/2026 12:45:23 pm |
| Market Cap: | $17,774,070 |
|---|---|
| Float: | 39,126,900 |
| Insiders Ownership: | 0.21% |
| Institutions: | 18 |
| Short Percent: | N/A |
| Industry: | Biotechnology & Life Sciences |
| Sector: | Healthcare |
| Website: | https://www.fibrobiologics.com |
| Country: | US |
| City: | Houston |
Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI FAQ is based on asking OpenAI questions about FibroBiologics Inc. (NASDAQ: FBLG).
Link your X account with Market Wire News to automatically tweet trending stocks news and your portfolio stocks news.